dihydroorotate dehydrogenase inhibitor ASLAN003
Term · Oncology and biomedicine · MLC-T-ONC-013054
An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, ASLAN003 specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.
| Identifier | MLC-T-ONC-013054 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | DHODH inhibitor ASLAN003 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013054",
"term": "dihydroorotate dehydrogenase inhibitor ASLAN003",
"field": "Oncology and biomedicine",
"definition": "An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, ASLAN003 specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.",
"synonyms": [
"DHODH inhibitor ASLAN003"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dihydroorotate-dehydrogenase-inhibitor-aslan003/"
}
Record 6,008 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.